Insmed Inc. to Webcast 2006 First Quarter Financial Results Conference Call, Monday May 8, 2006 at 4:30 p.m. (ET)
02 Mai 2006 - 10:27PM
Business Wire
Insmed (NASDAQ:INSM) announced today that it will release its 2006
first quarter financial results on Monday, May 8, 2006 after market
close. The Company will host a conference call on Monday, May 8 at
4:30 p.m. Eastern Time to discuss the financial results and provide
a business update. Interested investors can listen to the call over
the internet from Insmed's investor relations website at
www.insmed.com or by dialing 800-475-3716 (domestic) or
719-457-2728 (international). A telephonic replay of the call will
be available for one week at 888-203-1112 (domestic) or
719-457-0820 (international), passcode: 9480743. A web replay of
the call will be available through the corporate website beginning
at 6:00 p.m. About Insmed Incorporated Insmed is a
biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic
diseases and endocrine disorders with unmet medical needs. For more
information, please visit www.insmed.com. The company's leading
product, IPLEX was approved as an orphan drug by the United States
Food and Drug Administration in December 2005 for the treatment of
growth failure in children with severe primary IGF-I deficiency
(Primary IGFD) or with growth hormone (GH) gene deletion who have
developed neutralizing antibodies to GH. About IPLEX IPLEX, a
complex of recombinant human IGF-I and its binding protein IGFBP-3
(rhIGF-I/rhIGFBP-3), is the only once-daily IGF-I replacement
therapy. It is also the only FDA-approved therapy that provides
both IGF-I and IGFBP-3 to treat children with severe primary IGFD.
The drug, to be launched during the second quarter of 2006, is also
being investigated for various other indications with unmet medical
needs, including extreme insulin resistance, myotonic muscular
dystrophy and HIV Associated Adipose Redistribution Syndrome
(HARS). About the Condition Severe primary IGFD is a genetic or
acquired condition in which patients do not generate sufficient
quantities of insulin-like growth factor-I (IGF-I) due to defect in
the growth hormone (GH) receptor/IGF-I pathway. Gene mutations
leading to growth failure due to IGF-I deficiency have been
identified in the growth hormone receptor, in the GH receptor
signalling pathway, and in the IGF-I gene itself. Patients with
severe primary IGFD present with marked short stature and a poor
prognosis for adult stature. Statements included within this press
release, which are not historical in nature, may constitute
forward-looking statements for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements regarding planned clinical trial design,
our regulatory and business strategies, plans and objectives of
management and growth opportunities for existing or proposed
products. Such forward-looking statements are subject to numerous
risks and uncertainties, including risks that product candidates
may fail in the clinic or may not be successfully marketed or
manufactured, the company may lack financial resources to complete
development of product candidates, the FDA may interpret the
results of our studies differently than we have, competing products
may be more successful, demand for new pharmaceutical products may
decrease, the biopharmaceutical industry may experience negative
market trends and other risks detailed from time to time in the
company's filings with the Securities and Exchange Commission. As a
result of these and other risks and uncertainties, actual results
may differ materially from those described in this press release.
For further information with respect to factors that could cause
actual results to differ from expectations, reference is made to
reports filed by the Company with the Securities and Exchange
Commission under the Securities Exchange Act of 1934, as amended.
The forward-looking statements made in this release are made only
as of the date hereof and Insmed disclaims any intention or
responsibility for updating predictions or financial guidance
contained in this release.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024